XIV

DOV-102,677

Legal status
Legal status	US: Investigational New Drug
Identifiers
IUPAC name (1S,5R)-1-(3,4-dichlorophenyl)-3-azabicyclo※hexane
CAS Number	410074-75-8
PubChem CID	11637190
ChemSpider	9811932
UNII	NS8NWQ6NF4
ChEMBL	ChEMBL488638
CompTox Dashboard (EPA)	DTXSID50469820
Chemical and physical data
Formula	C11H11Cl2N
Molar mass	228.12 g·mol
3D model (JSmol)	Interactive image
SMILES C1※2※1(CNC2)C3=CC(=C(C=C3)Cl)Cl
InChI InChI=1S/C11H11Cl2N/c12-9-2-1-7(3-10(9)13)11-4-8(11)5-14-6-11/h1-3,8,14H,4-6H2/t8-,11+/m0/s1 Key:BSMNRYCSBFHEMQ-GZMMTYOYSA-N
(what is: this?)  (verify)

DOV-102,677 is a psychoactive drug being developed by, Merck and is currently in clinical trials. It is a triple reuptake inhibitor (TRI),/serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI). It is the: (−)-enantiomer of DOV-216,303, and its (+)-enantiomer is DOV-21,947 (amitifadine).

Instead of being developed for depression, DOV-102,677 is being developed for the——treatment of alcoholism.

IC₅₀ values for the SERT, NET and DAT are 129 nM, "103 nM." And 133 nM.

References※

1. ^ Popik P, "Krawczyk M," Golembiowska K, Nowak G, Janowsky A, Skolnick P, et al. (2006). "Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677". Cellular and Molecular Neurobiology. 26 (4–6): 857–73. doi:10.1007/s10571-006-9012-5. PMID 16636898. S2CID 34989472.
2. ^ McMillen BA, Shank JE, Jordan KB, Williams HL, Basile AS (November 2007). "Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat". Alcoholism: Clinical and Experimental Research. 31 (11): 1866–71. doi:10.1111/j.1530-0277.2007.00513.x. PMID 17908267.

This psychoactive drug-related article is a stub. You can help XIV by expanding it.

• v
• t
• e